Elucidating Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patients
阐明丙型肝炎感染是 HIV 感染者患冠心病的危险因素
基本信息
- 批准号:10452333
- 负责人:
- 金额:$ 4.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAdultAfrican AmericanAgeAngiographyAtherosclerosisBaltimoreCD4 Positive T LymphocytesCD8B1 geneCXCL10 geneCXCL11 geneCXCL9 geneCardiovascular systemCaucasiansCessation of lifeChronicChronic Hepatitis CClinicClinicalClinical InvestigatorCohort StudiesCommunicable DiseasesCoronaryCoronary ArteriosclerosisCoronary heart diseaseCross-Sectional StudiesDataDiseaseDisease ProgressionDrug userEpidemicExtrahepaticFeasibility StudiesGeneral PopulationGoalsHIVHIV/HCVHLA-DR AntigensHeart DiseasesHeart RateHepatitis CHepatitis C TherapyHepatitis C co-infectionHumanIllicit DrugsImmuneIndividualInfectionInflammationInflammatoryInstitutesIntegration Host FactorsInterferon Type IIInterleukin-6InterventionLeadLinkLiver FibrosisManuscriptsMarylandMeasuresMorbidity - disease rateParticipantPathogenesisPathway interactionsPatientsPlasmaPopulationPublishingRecording of previous eventsRetrospective cohort studyRiskRisk FactorsRoleT memory cellT-Cell ActivationTNF geneTestingTherapeutic InterventionTimeUnited StatesUniversitiesUpdateViral ProteinsVirus DiseasesWomanWorkantiretroviral therapybaseburden of illnesscardiovascular risk factorcohortcoronary calcium scoringcoronary plaquedesignexhaustexhaustionheart disease riskhigh riskhigh risk populationimmune activationindividual patientinflammatory markerinner citymalemedical schoolsmortalitynovelpreventive interventionprofessorprogrammed cell death protein 1sextherapeutic targetvirology
项目摘要
PROJECT ABSTRACT
The candidate is an Assistant Professor at the University of Maryland School of Medicine in
Division of Infectious Disease and the Institute of Human Virology. The candidate's long-term
goal is to become an independent clinical investigator and to contribute to the field of discovery
in HIV/AIDS and hepatitis C (HCV). The specific focus is on identifying mechanistic pathways
that confer the increased cardiovascular morbidity and mortality with hopes of developing
therapeutic targets to reduce the burden of coronary heart disease (CHD) in these patients.
The candidate has shown initiative by conducting a longitudinal retrospective cohort study of
patients in one of the largest HIV clinics in inner-city Baltimore. Preliminary data demonstrated
an association between chronic HCV infection and elevated risk scores for developing CHD in
this high-risk population. This result led to the hypothesis for the proposed project as well as
another pilot feasibility study evaluating coronary atherosclerosis using coronary CT
angiography in these patients. Two manuscripts have been published, and four others are in
review related to this work.
Rates of CHD are over twice as high in HIV-infected compared to matched uninfected controls,
but factors contributing to increased risk of CHD in HIV-infected patients remain to be clearly
elucidated. Many studies suggest that HCV co-infection is associated with increased rates of
CHD in HIV-infected patients, but results have been mixed. Preliminary data from the
candidate’s work suggest that HCV found an association between HCV and CHD in an inner-
city, high-risk demographic group and therefore provides strong scientific premise to design a
study that will more conclusively delineate this unresolved relationship between HCV and CHD.
The goal of this proposal is to establish the extent to which chronic HCV infection increases the
burden of CHD in HIV-infected patients, and to elucidate host inflammatory and immune
pathways that predict increased CHD burden. We hypothesize that chronic HCV infection in HIV
patients increases CHD risk by inducing inflammation and T cell activation that contribute to
accelerated progression of CHD. To test our hypothesis, we will use novel non-interferon based
therapy to eradicate HCV infection and test whether atherosclerosis decreases, and in doing so,
establish a causal link between HCV and atherosclerosis. Identifying predictors of CHD
progression from overlapping pathways could inform preventive and therapeutic intervention
strategies to mitigate CHD progression in HIV/HCV co-infected patients.
项目摘要
该候选人是马里兰大学医学院的助理教授
传染病科和人类病毒学研究所的候选人的长期。
目标是成为一名独立的临床研究者并为发现领域做出贡献
艾滋病毒/艾滋病和丙型肝炎(HCV)的具体重点是确定机制途径。
这导致心血管发病率和死亡率增加,并有望发展
目标是减轻这些患者的冠心病(CHD)负担。
候选人通过进行纵向回顾性队列研究表现出了主动性
初步数据显示,巴尔的摩市中心最大的艾滋病诊所之一的患者。
慢性 HCV 感染与患 CHD 的风险评分升高之间存在关联
这个高风险人群得出了拟议项目的假设。
另一项利用冠状动脉 CT 评估冠状动脉粥样硬化的试点可行性研究
这些患者的血管造影术已发表,另外四篇已发表。
审查与这项工作相关的内容。
艾滋病毒感染者的冠心病发病率是未感染者的两倍多,
但导致艾滋病毒感染者患冠心病风险增加的因素仍有待明确
许多研究表明,HCV 合并感染与感染率增加有关。
HIV 感染者可能患有先天性心脏病,但初步数据结果好坏参半。
候选人的工作表明,HCV 发现 HCV 和 CHD 之间存在内在关联。
城市、高危人群,为设计
这项研究将更明确地描述 HCV 和 CHD 之间这一尚未解决的关系。
该提案的目标是确定慢性 HCV 感染在多大程度上增加了
HIV 感染者的 CHD 负担,并阐明宿主炎症和免疫
我们与艾滋病毒中的慢性丙型肝炎病毒感染作斗争。
患者通过诱导炎症和 T 细胞激活来增加冠心病风险
为了检验我们的假设,我们将使用基于新型非干扰素的药物。
根除 HCV 感染并测试动脉粥样硬化是否减少的疗法,在此过程中,
确定 HCV 与动脉粥样硬化之间的因果关系。
重叠途径可以为预防进展和治疗干预提供信息
减缓 HIV/HCV 合并感染患者 CHD 进展的策略。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Association of Soluble Markers of Inflammation With Peri-coronary Artery Inflammation in People With and Without HIV Infection and Without Cardiovascular Disease.
- DOI:10.1093/ofid/ofad328
- 发表时间:2023-08
- 期刊:
- 影响因子:4.2
- 作者:
- 通讯作者:
The Role of Multimodality Imaging in HIV-Associated Cardiomyopathy.
- DOI:10.3389/fcvm.2021.811593
- 发表时间:2021
- 期刊:
- 影响因子:3.6
- 作者:Gambahaya ET;Rana R;Bagchi S;Sharma G;Sarkar S;Goerlich E;Cupido B;Mukherjee M;Hays AG
- 通讯作者:Hays AG
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shashwatee Bagchi其他文献
Shashwatee Bagchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
单核细胞产生S100A8/A9放大中性粒细胞炎症反应调控成人Still病发病及病情演变的机制研究
- 批准号:82373465
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SERPINF1/SRSF6/B7-H3信号通路在成人B-ALL免疫逃逸中的作用及机制研究
- 批准号:82300208
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于动态信息的深度学习辅助设计成人脊柱畸形手术方案的研究
- 批准号:82372499
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Intervening with Haitian Immigrants in the U.S. to Improve HIV Outcomes
对美国的海地移民进行干预以改善艾滋病毒感染结果
- 批准号:
10700451 - 财政年份:2023
- 资助金额:
$ 4.34万 - 项目类别:
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
用于治疗 HIV 诊所兴奋剂使用的 reSET:护理优化支持治疗依从性 (COSTA)
- 批准号:
10553554 - 财政年份:2022
- 资助金额:
$ 4.34万 - 项目类别:
PEARL 2.0: The impact of the Ending the HIV Epidemic initiative and risk factor interventions on the projected multimorbidity burden and healthcare costs for people aging with HIV in the United States
PEARL 2.0:“结束艾滋病毒流行”倡议和风险因素干预措施对美国艾滋病毒感染者的预计多重病负担和医疗保健费用的影响
- 批准号:
10632482 - 财政年份:2022
- 资助金额:
$ 4.34万 - 项目类别:
Baylor College of Medicine Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional)
贝勒医学院站点联盟 - HIV/艾滋病干预青少年医学试验网络 (ATN) 运营和合作中心(UM2 临床试验可选)
- 批准号:
10599557 - 财政年份:2022
- 资助金额:
$ 4.34万 - 项目类别:
Understanding the Role of Neighborhoods on Urban Youth's Substance Use and Mental Health: A Community-Based Substance Abuse Prevention Project
了解社区对城市青年药物滥用和心理健康的作用:基于社区的药物滥用预防项目
- 批准号:
10675818 - 财政年份:2021
- 资助金额:
$ 4.34万 - 项目类别: